April 24th 2024
During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
ABCP Regimen Shows OS Benefit in Secondline NSCLC With EGFR Sensitizing Mutations
March 15th 2022In a subgroup analysis of patients with non-small cell lung cancer who have EGFR sensitizing mutations, the regimen of atezolizumab plus bevacizumab plus carboplatin, and paclitaxel, had a stonger survival benefit compared to other therapies.
Read More
Roundtable Discussion: Dowlati Debates the Role of Osimertinib in Adjuvant Treatment of NSCLC
February 3rd 2022During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, and participants discussed the challenges of molecular testing and how to use test results to introduce targeted treatments for patients with non–small cell lung cancer.
Read More
FDA Grants Breakthrough Therapy Designation to DZD9008 for EGFR Exon20Ins-Positive NSCLC
January 27th 2022DZD9008 for the treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring with EGFR exon20 insertion mutations is an investigative treatment strategy in a clinical trial.
Read More
Efficacy of Mobocertinib Lowered by Dose Reductions in EGFR+ NSCLC
January 18th 2022Danny Nguyen, MD, discusses an analysis of efficacy and adverse events of mobocertinib in patients with EGFR-positive non–small cell lung cancer that was presented at the European Society for Medical Oncology 2021 Congress.
Watch
Patritumab deruxtecan has been granted a breakthrough therapy designation by the FDA to accelerate its development for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.
Read More
High pCR Rate Shows Potential for Neoadjuvant Osimertinib in EGFR+ NSCLC
October 24th 2021Neoadjuvant osimertinib may lead to a better mechanistic understanding of what drives incomplete response and residual disease for patients with EGFR-mutant NSCLC. according to Collin M. Blakely, MD, PhD.
Read More
Osimertinib Plus Bevacizumab Does Not Improve PFS in EGFR-Mutated NSCLC
September 18th 2021Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.
Read More
Roundtable Discussion: Osimertinib Is Chosen as Best Option for Frontline Therapy for EGFR+ NSCLC
August 22nd 2021During a Targeted Oncology Case-Based Roundtable event, Miguel Albino, MD, of Texas Oncology, discussed the case of a 73-year-old patient with EGFR-mutant non–small cell lung cancer.
Read More
Plinabulin Plus Docetaxel Combination Succeeds in Improving OS in NSCLC With EGFR Wild Type
August 4th 2021The combination of plinabulin with docetaxel showed improvement in overall survival compared with docetaxel alone as treatment of patients with second- and third-line non –small cell lung cancer with EGFR wild type, meeting the primary end point of the phase 3 DUBLIN-3 clinical trial.
Read More